Cargando…

Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin

Although leiomyosarcomas (LMSs) form the largest subgroup of soft tissue sarcomas (STSs), the efficacy of chemotherapy in this group is largely unclear, partly because older studies are contaminated with gastrointestinal stromal tumors (GISTs). In this retrospective study we investigated the outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Oosten, A. W., Seynaeve, C., Schmitz, P. I. M., den Bakker, M. A., Verweij, J., Sleijfer, S.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801456/
https://www.ncbi.nlm.nih.gov/pubmed/20066161
http://dx.doi.org/10.1155/2009/348910
_version_ 1782175923030720512
author Oosten, A. W.
Seynaeve, C.
Schmitz, P. I. M.
den Bakker, M. A.
Verweij, J.
Sleijfer, S.
author_facet Oosten, A. W.
Seynaeve, C.
Schmitz, P. I. M.
den Bakker, M. A.
Verweij, J.
Sleijfer, S.
author_sort Oosten, A. W.
collection PubMed
description Although leiomyosarcomas (LMSs) form the largest subgroup of soft tissue sarcomas (STSs), the efficacy of chemotherapy in this group is largely unclear, partly because older studies are contaminated with gastrointestinal stromal tumors (GISTs). In this retrospective study we investigated the outcome of first line chemotherapy in 65 patients with unresectable or metastatic LMS. The overall response rate (ORR) was 18%; and the median progression-free (PFS) and overall survival (OS) were 3.8 and 9.7 months respectively. No statistically significant differences in outcomes for uterine and non-uterine LMS were found. In non-uterine LMS, however, the PFS and OS seemed to be longer for females than for males, potentially negatively affecting outcomes in this group. If our observations are confirmed in other series, they would suggest that studies performed in STS patients should not only stratify for histological subtype but also for uterine versus non-uterine LMS and for gender.
format Text
id pubmed-2801456
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-28014562010-01-11 Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin Oosten, A. W. Seynaeve, C. Schmitz, P. I. M. den Bakker, M. A. Verweij, J. Sleijfer, S. Sarcoma Research Article Although leiomyosarcomas (LMSs) form the largest subgroup of soft tissue sarcomas (STSs), the efficacy of chemotherapy in this group is largely unclear, partly because older studies are contaminated with gastrointestinal stromal tumors (GISTs). In this retrospective study we investigated the outcome of first line chemotherapy in 65 patients with unresectable or metastatic LMS. The overall response rate (ORR) was 18%; and the median progression-free (PFS) and overall survival (OS) were 3.8 and 9.7 months respectively. No statistically significant differences in outcomes for uterine and non-uterine LMS were found. In non-uterine LMS, however, the PFS and OS seemed to be longer for females than for males, potentially negatively affecting outcomes in this group. If our observations are confirmed in other series, they would suggest that studies performed in STS patients should not only stratify for histological subtype but also for uterine versus non-uterine LMS and for gender. Hindawi Publishing Corporation 2009 2009-12-29 /pmc/articles/PMC2801456/ /pubmed/20066161 http://dx.doi.org/10.1155/2009/348910 Text en Copyright © 2009 A. W. Oosten et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Oosten, A. W.
Seynaeve, C.
Schmitz, P. I. M.
den Bakker, M. A.
Verweij, J.
Sleijfer, S.
Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin
title Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin
title_full Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin
title_fullStr Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin
title_full_unstemmed Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin
title_short Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin
title_sort outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801456/
https://www.ncbi.nlm.nih.gov/pubmed/20066161
http://dx.doi.org/10.1155/2009/348910
work_keys_str_mv AT oostenaw outcomesoffirstlinechemotherapyinpatientswithadvancedormetastaticleiomyosarcomaofuterineandnonuterineorigin
AT seynaevec outcomesoffirstlinechemotherapyinpatientswithadvancedormetastaticleiomyosarcomaofuterineandnonuterineorigin
AT schmitzpim outcomesoffirstlinechemotherapyinpatientswithadvancedormetastaticleiomyosarcomaofuterineandnonuterineorigin
AT denbakkerma outcomesoffirstlinechemotherapyinpatientswithadvancedormetastaticleiomyosarcomaofuterineandnonuterineorigin
AT verweijj outcomesoffirstlinechemotherapyinpatientswithadvancedormetastaticleiomyosarcomaofuterineandnonuterineorigin
AT sleijfers outcomesoffirstlinechemotherapyinpatientswithadvancedormetastaticleiomyosarcomaofuterineandnonuterineorigin